Deferasirox
- 地拉罗司；ICL 670
货号： abs817234
| 货号-规格 | 货期 | 价格 | 数量 |
| abs817234-2mg | 1-2周 | ￥467.00 | - + |
| abs817234-5mg | 1-2周 | ￥816.00 | - + |
| abs817234-10mg | 1-2周 | ￥1469.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. | |
| 纯度 | 99% | |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. | |
| 基本信息 | ||
| 别名 | 地拉罗司；ICL 670 | |
| 外观 | 白色至淡黄色性粉末 | |
| 可溶性/溶解性 | DMSO : 69 mg/mL (184.8 mM) Ethanol : 2 mg/mL (5.35 mM) | |
| 生物活性 | ||
| 靶点 | iron | |
| In vitro(体外研究) | In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner. | |
| In vivo(体内研究) | The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy. | |
| 参考文献 | ||
| 参考文献 | ||
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 实验方法 实验条件
共 0张，还能上传 8张 提交
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要提问”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
促销资讯 更多
订购信息
您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商，请从以下的下拉列表中选择。
